JP2017523188A - Ｂｔｋ阻害剤を伴う治療に対するｄｌｂｃｌの応答を予測するためのバイオマーカー - Google Patents

Ｂｔｋ阻害剤を伴う治療に対するｄｌｂｃｌの応答を予測するためのバイオマーカー Download PDF

Info

Publication number
JP2017523188A
JP2017523188A JP2017504752A JP2017504752A JP2017523188A JP 2017523188 A JP2017523188 A JP 2017523188A JP 2017504752 A JP2017504752 A JP 2017504752A JP 2017504752 A JP2017504752 A JP 2017504752A JP 2017523188 A JP2017523188 A JP 2017523188A
Authority
JP
Japan
Prior art keywords
dlbcl
ibrutinib
modification
inhibitor
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017504752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523188A5 (enExample
Inventor
シュヴァイクホファー，カール
エッカート，カール
クオ，ス−ピン
チャン，ベティー
ボープレ，ダリン
チュン，レオ
Original Assignee
ファーマサイクリックス エルエルシー
ファーマサイクリックス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマサイクリックス エルエルシー, ファーマサイクリックス エルエルシー filed Critical ファーマサイクリックス エルエルシー
Publication of JP2017523188A publication Critical patent/JP2017523188A/ja
Publication of JP2017523188A5 publication Critical patent/JP2017523188A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017504752A 2014-08-01 2015-07-31 Ｂｔｋ阻害剤を伴う治療に対するｄｌｂｃｌの応答を予測するためのバイオマーカー Pending JP2017523188A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462032430P 2014-08-01 2014-08-01
US62/032,430 2014-08-01
US201562119668P 2015-02-23 2015-02-23
US62/119,668 2015-02-23
US201562127484P 2015-03-03 2015-03-03
US62/127,484 2015-03-03
PCT/US2015/043300 WO2016019341A1 (en) 2014-08-01 2015-07-31 Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor

Publications (2)

Publication Number Publication Date
JP2017523188A true JP2017523188A (ja) 2017-08-17
JP2017523188A5 JP2017523188A5 (enExample) 2018-09-13

Family

ID=55179406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017504752A Pending JP2017523188A (ja) 2014-08-01 2015-07-31 Ｂｔｋ阻害剤を伴う治療に対するｄｌｂｃｌの応答を予測するためのバイオマーカー

Country Status (13)

Country Link
US (1) US20160032404A1 (enExample)
EP (1) EP3185870A4 (enExample)
JP (1) JP2017523188A (enExample)
KR (1) KR20170042614A (enExample)
CN (1) CN106714804A (enExample)
AU (1) AU2015296010A1 (enExample)
BR (1) BR112017001677A2 (enExample)
CA (1) CA2955744A1 (enExample)
IL (1) IL250221A0 (enExample)
MX (1) MX2017001302A (enExample)
RU (1) RU2017106794A (enExample)
SG (1) SG11201700774UA (enExample)
WO (1) WO2016019341A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021527097A (ja) * 2018-06-15 2021-10-11 ヤンセン ファーマシューティカ エヌ．ベー． イブルチニブを含む配合物／組成物
JP2022513666A (ja) * 2018-11-30 2022-02-09 ヤンセン バイオテツク，インコーポレーテツド 濾胞性リンパ腫の治療方法
JP2023154581A (ja) * 2022-04-07 2023-10-20 学校法人藤田学園 不明熱患者のｂ細胞リンパ腫診断補助キットおよび情報提供方法
JP7696987B1 (ja) 2023-12-22 2025-06-23 東洋鋼鈑株式会社 遺伝子変異を検出する方法
JP7698850B1 (ja) 2023-12-22 2025-06-26 東洋鋼鈑株式会社 遺伝子変異評価用キット

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
HRP20140309T1 (hr) 2008-10-22 2014-05-09 Array Biopharma, Inc. SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
KR102015402B1 (ko) 2010-05-20 2019-08-28 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
WO2016071770A2 (en) * 2014-11-05 2016-05-12 Janssen Pharmaceutica Nv Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same
JP6914834B2 (ja) 2014-11-16 2021-08-04 アレイ バイオファーマ インコーポレイテッド （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形
PL3892302T3 (pl) 2015-04-06 2024-03-11 Janssen Pharmaceutica Nv Kompozycje zawierające ibrutynib
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
AU2017246554B2 (en) 2016-04-04 2022-08-18 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
KR102566858B1 (ko) 2016-05-18 2023-08-11 어레이 바이오파마 인크. (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US11085039B2 (en) 2016-12-12 2021-08-10 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays
US11473081B2 (en) 2016-12-12 2022-10-18 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays
US11156626B2 (en) 2016-12-30 2021-10-26 xCella Biosciences, Inc. Multi-stage sample recovery system
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
EP3612192A4 (en) * 2017-06-08 2020-05-27 Enlivex Therapeutics Ltd. THERAPEUTIC APOPTOTIC CELLS FOR CANCER THERAPY
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
GB2577909B (en) * 2018-10-10 2020-11-18 Symetrica Ltd Gamma-ray spectrum classification
EP3890876B1 (en) 2018-12-06 2024-05-01 Xcella Biosciences, Inc. Lateral loading of microcapillary arrays
WO2021087044A1 (en) * 2019-10-30 2021-05-06 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
WO2022169731A1 (en) * 2021-02-03 2022-08-11 Curis Inc. Biomarkers for fimepinostat therapy
BR112023025459A2 (pt) 2021-06-04 2024-02-27 Janssen Pharmaceutica Nv Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos
WO2023275330A1 (en) * 2021-06-30 2023-01-05 Janssen Pharmaceutica Nv Treatments for diffuse large b-cell lymphoma
CA3223610A1 (en) * 2021-06-30 2023-01-05 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
CN121969770A (zh) * 2023-10-09 2026-05-01 百时美施贵宝公司 预测淋巴瘤对药物的反应性的方法以及治疗淋巴瘤的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160206A1 (en) * 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
WO2013059738A2 (en) * 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
WO2013063401A1 (en) * 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
WO2014018567A1 (en) * 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ772688A (en) * 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2013184572A1 (en) * 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2014110114A1 (en) * 2013-01-10 2014-07-17 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160206A1 (en) * 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
WO2013059738A2 (en) * 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
WO2013063401A1 (en) * 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
WO2014018567A1 (en) * 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOOD, 2011, VOL. 118, NO. 21, P. 1131, ABSTRACT 2633, JPN6019011959, ISSN: 0004011731 *
BLOOD, 2012, VOL. 120, NO. 21, ABSTRACT 686, JPN7019001016, ISSN: 0004144196 *
CANCER RESEARCH, 2011, VOL. 71, NO. 8 SUPPLEMENT, ABSTRACT 3590, JPN7019001017, ISSN: 0004011730 *
GENES, CHROMOSOMES & CANCER, 2013.11.05, VOL. 53, NO. 2, PP. 144-153, JPN6019011956, ISSN: 0004144197 *
HUMAN PATHOLOGY, 2014.03, VOL. 45, NO. 3, PP. 556-564, JPN6019011957, ISSN: 0004144198 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7853261B2 (ja) 2018-06-15 2026-04-28 ヤンセン ファーマシューティカ エヌ．ベー． イブルチニブを含む配合物／組成物
JP2024023262A (ja) * 2018-06-15 2024-02-21 ヤンセン ファーマシューティカ エヌ．ベー． イブルチニブを含む配合物／組成物
JP7695078B2 (ja) 2018-06-15 2025-06-18 ヤンセン ファーマシューティカ エヌ．ベー． イブルチニブを含む配合物／組成物
JP2021527097A (ja) * 2018-06-15 2021-10-11 ヤンセン ファーマシューティカ エヌ．ベー． イブルチニブを含む配合物／組成物
JP2022513666A (ja) * 2018-11-30 2022-02-09 ヤンセン バイオテツク，インコーポレーテツド 濾胞性リンパ腫の治療方法
JP2023154581A (ja) * 2022-04-07 2023-10-20 学校法人藤田学園 不明熱患者のｂ細胞リンパ腫診断補助キットおよび情報提供方法
JP7423090B2 (ja) 2022-04-07 2024-01-29 学校法人藤田学園 不明熱患者のｂ細胞リンパ腫診断補助キットおよび情報提供方法
JP7696987B1 (ja) 2023-12-22 2025-06-23 東洋鋼鈑株式会社 遺伝子変異を検出する方法
JP7698850B1 (ja) 2023-12-22 2025-06-26 東洋鋼鈑株式会社 遺伝子変異評価用キット
WO2025134830A1 (ja) * 2023-12-22 2025-06-26 東洋鋼鈑株式会社 遺伝子変異評価用キット
JP2025099659A (ja) * 2023-12-22 2025-07-03 東洋鋼鈑株式会社 遺伝子変異評価用キット
JP2025099699A (ja) * 2023-12-22 2025-07-03 東洋鋼鈑株式会社 遺伝子変異を検出する方法
WO2025134829A1 (ja) * 2023-12-22 2025-06-26 東洋鋼鈑株式会社 遺伝子変異を検出する方法

Also Published As

Publication number Publication date
US20160032404A1 (en) 2016-02-04
BR112017001677A2 (pt) 2018-07-17
CA2955744A1 (en) 2016-02-04
IL250221A0 (en) 2017-03-30
AU2015296010A1 (en) 2017-02-02
RU2017106794A (ru) 2018-09-03
CN106714804A (zh) 2017-05-24
SG11201700774UA (en) 2017-02-27
MX2017001302A (es) 2017-10-11
EP3185870A4 (en) 2018-06-20
EP3185870A1 (en) 2017-07-05
KR20170042614A (ko) 2017-04-19
RU2017106794A3 (enExample) 2019-02-27
WO2016019341A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
JP7795513B2 (ja) ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用
US11318138B2 (en) Methods for treating B cell proliferative disorders
US20160032404A1 (en) Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
US9730938B2 (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof
JP6588515B2 (ja) ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用
CN117642168A (zh) 布鲁顿酪氨酸激酶的抑制剂及其使用方法
HK40102175A (zh) 布鲁顿酪氨酸激酶的抑制剂及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180731

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191105